Annual Incidence Rates per 100 000 Person-Years of 13-Valent Pneumococcal Conjugate Vaccine Serotype Invasive Pneumococcal Disease by Demographic Characteristics Over Time—Data From 20 Counties in Tennessee, 1998–2016
| Characteristic . | Pre-PCV7 (1998–1999) (n = 601) . | . | . | Pre-PCV13 (2001–2009) (n = 2032) . | . | . | Post-PCV13 (2011–2016) (n = 561) . | . | . |
|---|---|---|---|---|---|---|---|---|---|
| . | Incidence (95% CI) . | Rate Ratio (95% CI) . | Rate Difference (95% CI) . | Incidence (95% CI) . | Rate Ratio (95% CI) . | Rate Difference (95% CI) . | Incidence (95% CI) . | Rate Ratio (95% CI) . | Rate Difference (95% CI) . |
| Age, y | |||||||||
| <18 | 16.2 (13.9–18.5) | … | … | 6.5 (5.9–7.1) | … | … | 0.8 (.6–1.0) | … | … |
| 18–64 | 7.6 (6.6–8.6) | 0.5 (.3–.7) | –8.6 (–11.1 to –6.1) | 6.7 (6.3–7.1) | 1 (.9–1.2) | 0.2 (–.5 to .9) | 2.3 (2.1–2.5) | 2.9 (2.5–3.3) | 1.5 (1.2–1.8) |
| ≥65 | 38.2 (32.8–43.6) | 2.4 (2–2.7) | 22 (16.1–27.9) | 19.5 (17.8–21.2) | 3 (2.7–3.3) | 13 (11.2–14.8) | 6.5 (5.5–7.5) | 8.1 (7–9.5) | 5.7 (4.7–6.7) |
| Sex | |||||||||
| Male | 14.5 (12.9–16.1) | … | … | 8.7 (8.2–9.2) | … | … | 2.7 (2.4–3.0) | … | … |
| Female | 11.9 (10.5–13.3) | 0.8 (.7–1) | –2.6 (–4.7 to –.5) | 7.4 (6.9–7.9) | 0.9 (.8–.9) | –1.3 (–2 to –.6) | 2.3 (2.0–2.6) | 0.9 (.7–1) | –0.4 (–.8 to 0) |
| Race | |||||||||
| White | 11.8 (10.6–13.0) | … | … | 7.4 (7.0–7.8) | … | … | 2.7 (2.4–3.0) | … | … |
| Black | 17.3 (15.1–19.5) | 1.5 (1.3–1.7) | 5.5 (3–8) | 10.8 (10.0–11.6) | 1.5 (1.3–1.6) | 3.4 (2.5–4.3) | 2.2 (1.8–2.6) | 0.8 (.7–1) | –0.5 (–1 to 0) |
| Other | 4.8 (1.8–7.8) | 0.4 (.2–.8) | –7 (–10.2 to –3.8) | 0.9 (.3–1.5) | 0.1 (.1–.3) | –6.5 (–7.2 to –5.8) | 0.1 (.0–.2) | 0 (0–.7) | –2.6 (–2.9 to –2.3) |
| Characteristic . | Pre-PCV7 (1998–1999) (n = 601) . | . | . | Pre-PCV13 (2001–2009) (n = 2032) . | . | . | Post-PCV13 (2011–2016) (n = 561) . | . | . |
|---|---|---|---|---|---|---|---|---|---|
| . | Incidence (95% CI) . | Rate Ratio (95% CI) . | Rate Difference (95% CI) . | Incidence (95% CI) . | Rate Ratio (95% CI) . | Rate Difference (95% CI) . | Incidence (95% CI) . | Rate Ratio (95% CI) . | Rate Difference (95% CI) . |
| Age, y | |||||||||
| <18 | 16.2 (13.9–18.5) | … | … | 6.5 (5.9–7.1) | … | … | 0.8 (.6–1.0) | … | … |
| 18–64 | 7.6 (6.6–8.6) | 0.5 (.3–.7) | –8.6 (–11.1 to –6.1) | 6.7 (6.3–7.1) | 1 (.9–1.2) | 0.2 (–.5 to .9) | 2.3 (2.1–2.5) | 2.9 (2.5–3.3) | 1.5 (1.2–1.8) |
| ≥65 | 38.2 (32.8–43.6) | 2.4 (2–2.7) | 22 (16.1–27.9) | 19.5 (17.8–21.2) | 3 (2.7–3.3) | 13 (11.2–14.8) | 6.5 (5.5–7.5) | 8.1 (7–9.5) | 5.7 (4.7–6.7) |
| Sex | |||||||||
| Male | 14.5 (12.9–16.1) | … | … | 8.7 (8.2–9.2) | … | … | 2.7 (2.4–3.0) | … | … |
| Female | 11.9 (10.5–13.3) | 0.8 (.7–1) | –2.6 (–4.7 to –.5) | 7.4 (6.9–7.9) | 0.9 (.8–.9) | –1.3 (–2 to –.6) | 2.3 (2.0–2.6) | 0.9 (.7–1) | –0.4 (–.8 to 0) |
| Race | |||||||||
| White | 11.8 (10.6–13.0) | … | … | 7.4 (7.0–7.8) | … | … | 2.7 (2.4–3.0) | … | … |
| Black | 17.3 (15.1–19.5) | 1.5 (1.3–1.7) | 5.5 (3–8) | 10.8 (10.0–11.6) | 1.5 (1.3–1.6) | 3.4 (2.5–4.3) | 2.2 (1.8–2.6) | 0.8 (.7–1) | –0.5 (–1 to 0) |
| Other | 4.8 (1.8–7.8) | 0.4 (.2–.8) | –7 (–10.2 to –3.8) | 0.9 (.3–1.5) | 0.1 (.1–.3) | –6.5 (–7.2 to –5.8) | 0.1 (.0–.2) | 0 (0–.7) | –2.6 (–2.9 to –2.3) |
Statistics are presented only among nonmissing values.
Abbreviations: CI, confidence interval; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
Annual Incidence Rates per 100 000 Person-Years of 13-Valent Pneumococcal Conjugate Vaccine Serotype Invasive Pneumococcal Disease by Demographic Characteristics Over Time—Data From 20 Counties in Tennessee, 1998–2016
| Characteristic . | Pre-PCV7 (1998–1999) (n = 601) . | . | . | Pre-PCV13 (2001–2009) (n = 2032) . | . | . | Post-PCV13 (2011–2016) (n = 561) . | . | . |
|---|---|---|---|---|---|---|---|---|---|
| . | Incidence (95% CI) . | Rate Ratio (95% CI) . | Rate Difference (95% CI) . | Incidence (95% CI) . | Rate Ratio (95% CI) . | Rate Difference (95% CI) . | Incidence (95% CI) . | Rate Ratio (95% CI) . | Rate Difference (95% CI) . |
| Age, y | |||||||||
| <18 | 16.2 (13.9–18.5) | … | … | 6.5 (5.9–7.1) | … | … | 0.8 (.6–1.0) | … | … |
| 18–64 | 7.6 (6.6–8.6) | 0.5 (.3–.7) | –8.6 (–11.1 to –6.1) | 6.7 (6.3–7.1) | 1 (.9–1.2) | 0.2 (–.5 to .9) | 2.3 (2.1–2.5) | 2.9 (2.5–3.3) | 1.5 (1.2–1.8) |
| ≥65 | 38.2 (32.8–43.6) | 2.4 (2–2.7) | 22 (16.1–27.9) | 19.5 (17.8–21.2) | 3 (2.7–3.3) | 13 (11.2–14.8) | 6.5 (5.5–7.5) | 8.1 (7–9.5) | 5.7 (4.7–6.7) |
| Sex | |||||||||
| Male | 14.5 (12.9–16.1) | … | … | 8.7 (8.2–9.2) | … | … | 2.7 (2.4–3.0) | … | … |
| Female | 11.9 (10.5–13.3) | 0.8 (.7–1) | –2.6 (–4.7 to –.5) | 7.4 (6.9–7.9) | 0.9 (.8–.9) | –1.3 (–2 to –.6) | 2.3 (2.0–2.6) | 0.9 (.7–1) | –0.4 (–.8 to 0) |
| Race | |||||||||
| White | 11.8 (10.6–13.0) | … | … | 7.4 (7.0–7.8) | … | … | 2.7 (2.4–3.0) | … | … |
| Black | 17.3 (15.1–19.5) | 1.5 (1.3–1.7) | 5.5 (3–8) | 10.8 (10.0–11.6) | 1.5 (1.3–1.6) | 3.4 (2.5–4.3) | 2.2 (1.8–2.6) | 0.8 (.7–1) | –0.5 (–1 to 0) |
| Other | 4.8 (1.8–7.8) | 0.4 (.2–.8) | –7 (–10.2 to –3.8) | 0.9 (.3–1.5) | 0.1 (.1–.3) | –6.5 (–7.2 to –5.8) | 0.1 (.0–.2) | 0 (0–.7) | –2.6 (–2.9 to –2.3) |
| Characteristic . | Pre-PCV7 (1998–1999) (n = 601) . | . | . | Pre-PCV13 (2001–2009) (n = 2032) . | . | . | Post-PCV13 (2011–2016) (n = 561) . | . | . |
|---|---|---|---|---|---|---|---|---|---|
| . | Incidence (95% CI) . | Rate Ratio (95% CI) . | Rate Difference (95% CI) . | Incidence (95% CI) . | Rate Ratio (95% CI) . | Rate Difference (95% CI) . | Incidence (95% CI) . | Rate Ratio (95% CI) . | Rate Difference (95% CI) . |
| Age, y | |||||||||
| <18 | 16.2 (13.9–18.5) | … | … | 6.5 (5.9–7.1) | … | … | 0.8 (.6–1.0) | … | … |
| 18–64 | 7.6 (6.6–8.6) | 0.5 (.3–.7) | –8.6 (–11.1 to –6.1) | 6.7 (6.3–7.1) | 1 (.9–1.2) | 0.2 (–.5 to .9) | 2.3 (2.1–2.5) | 2.9 (2.5–3.3) | 1.5 (1.2–1.8) |
| ≥65 | 38.2 (32.8–43.6) | 2.4 (2–2.7) | 22 (16.1–27.9) | 19.5 (17.8–21.2) | 3 (2.7–3.3) | 13 (11.2–14.8) | 6.5 (5.5–7.5) | 8.1 (7–9.5) | 5.7 (4.7–6.7) |
| Sex | |||||||||
| Male | 14.5 (12.9–16.1) | … | … | 8.7 (8.2–9.2) | … | … | 2.7 (2.4–3.0) | … | … |
| Female | 11.9 (10.5–13.3) | 0.8 (.7–1) | –2.6 (–4.7 to –.5) | 7.4 (6.9–7.9) | 0.9 (.8–.9) | –1.3 (–2 to –.6) | 2.3 (2.0–2.6) | 0.9 (.7–1) | –0.4 (–.8 to 0) |
| Race | |||||||||
| White | 11.8 (10.6–13.0) | … | … | 7.4 (7.0–7.8) | … | … | 2.7 (2.4–3.0) | … | … |
| Black | 17.3 (15.1–19.5) | 1.5 (1.3–1.7) | 5.5 (3–8) | 10.8 (10.0–11.6) | 1.5 (1.3–1.6) | 3.4 (2.5–4.3) | 2.2 (1.8–2.6) | 0.8 (.7–1) | –0.5 (–1 to 0) |
| Other | 4.8 (1.8–7.8) | 0.4 (.2–.8) | –7 (–10.2 to –3.8) | 0.9 (.3–1.5) | 0.1 (.1–.3) | –6.5 (–7.2 to –5.8) | 0.1 (.0–.2) | 0 (0–.7) | –2.6 (–2.9 to –2.3) |
Statistics are presented only among nonmissing values.
Abbreviations: CI, confidence interval; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
